BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9837898)

  • 1. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor.
    Koopman JL; Slomp J; de Bart AC; Quax PH; Verheijen JH
    J Biol Chem; 1998 Dec; 273(50):33267-72. PubMed ID: 9837898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.
    Reuning U; Bang NU
    Arterioscler Thromb; 1992 Oct; 12(10):1161-70. PubMed ID: 1327097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
    Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
    J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor.
    Anichini E; Fibbi G; Pucci M; Caldini R; Chevanne M; Del Rosso M
    Exp Cell Res; 1994 Aug; 213(2):438-48. PubMed ID: 8050501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts.
    De Petro G; Copeta A; Barlati S
    Exp Cell Res; 1994 Jul; 213(1):286-94. PubMed ID: 8020601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation.
    Mirshahi SS; Lounes KC; Lu H; Pujade-Lauraine E; Mishal Z; Bénard J; Bernadou A; Soria C; Soria J
    FEBS Lett; 1997 Jul; 411(2-3):322-6. PubMed ID: 9271229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients.
    Fibbi G; Barletta E; Dini G; Del Rosso A; Pucci M; Cerletti M; Del Rosso M
    Lab Invest; 2001 Jan; 81(1):27-39. PubMed ID: 11204271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
    Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
    Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.
    Lau HK; Kim M; Koo J; Chiu B; Murray D
    Clin Exp Metastasis; 1995 Nov; 13(6):492-8. PubMed ID: 7586807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator.
    Bakker AH; Nieuwenbroek NM; Verheijen JH
    Protein Eng; 1995 Dec; 8(12):1295-1302. PubMed ID: 8869642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.
    Hajjar KA; Hamel NM
    J Biol Chem; 1990 Feb; 265(5):2908-16. PubMed ID: 2154465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor.
    Fibbi G; Caldini R; Chevanne M; Pucci M; Schiavone N; Morbidelli L; Parenti A; Granger HJ; Del Rosso M; Ziche M
    Lab Invest; 1998 Sep; 78(9):1109-19. PubMed ID: 9759655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
    Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
    Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
    Paciucci R; Vilá MR; Adell T; Díaz VM; Torà M; Nakamura T; Real FX
    Am J Pathol; 1998 Jul; 153(1):201-12. PubMed ID: 9665481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene response of human skin fibroblasts to urokinase- and tissue-type plasminogen activators.
    Copeta A; Tavian D; Marchina E; De Petro G; Barlati S
    Growth Factors; 2000; 17(4):249-68. PubMed ID: 10801075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
    Kirchheimer JC; Wojta J; Christ G; Binder BR
    Proc Natl Acad Sci U S A; 1989 Jul; 86(14):5424-8. PubMed ID: 2501786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells.
    Herbert JM; Lamarche I; Carmeliet P
    J Biol Chem; 1997 Sep; 272(38):23585-91. PubMed ID: 9295297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.